Dublin, June 28, 2023 (GLOBE NEWSWIRE) -- The "Viral Vector and Plasmid DNA Manufacturing Market - Global Forecast to 2028" report has been added to ResearchAndMarkets.com's offering.
The global viral vector and plasmid DNA manufacturing market is projected to reach USD 12.8 billion by 2028 from USD 5.5 billion in 2023, at a CAGR of 18.2%
The growth of this market can be attributed to the availability of funding for the development of gene therapy. Gene therapy is a rapidly growing field, and funding is needed for research and development, clinical trials, and manufacturing.
For instance, in December 2022, SonoThera, a biotechnology company announced the completion of its USD 60.75 million Series A financing round. The financing will support the continued development of SonoThera's ultrasound-guided, nonviral, gene therapy platform and treatments, designed to provide patients with genetic medicines.
The vector amplification, editing, and expansion segment accounted for the largest share by the upstream manufacturing process during the forecast period
In 2022, the vector amplification, editing and expansion segment accounted for the largest share by upstream manufacturing process in the global viral vector and plasmid DNA manufacturing market. Vector amplification, editing, and expansion are critical steps in viral vector and plasmid DNA manufacturing as they directly impact the quantity, quality, and functionality of the vectors.
The pharmaceutical and biopharmaceutical industry is witnessing significant advancements, particularly in the development of novel therapeutics and vaccines. Viral vectors and plasmid DNA are crucial tools for delivering therapeutic genes or vaccine antigens.
The demand for vector amplification, editing, and expansion is driven by the need to produce a diverse range of viral vectors and plasmid DNA for various therapeutic and vaccine candidates.
Europe: The second largest region in the viral vector and plasmid DNA manufacturing market
Europe accounted for the second-largest market for viral vector and plasmid DNA manufacturing market after North America. The European viral vector and plasmid DNA manufacturing market has witnessed significant growth in recent years, driven by various factors that have propelled its expansion.
Europe is at the forefront of developing and adopting emerging technologies in the field of viral vector and plasmid DNA manufacturing market. This includes advancements in viral vector and plasmid DNA manufacturing technologies. The adoption of these innovative technologies accelerates the progress of viral vector and plasmid DNA manufacturing research and expands its applications.
Additionally, Europe offers comprehensive training and education programs in viral vector and plasmid DNA manufacturing. Universities, research institutes, and organizations provide funding, and conferences to enhance the knowledge and skills of scientists and researchers.
The availability of funding promotes the adoption and utilization of viral vector and plasmid DNA manufacturing technologies in Europe.
Key Attributes:
| Report Attribute | Details |
| No. of Pages | 317 |
| Forecast Period | 2023 - 2028 |
| Estimated Market Value (USD) in 2023 | $5.5 Billion |
| Forecasted Market Value (USD) by 2028 | $12.8 Billion |
| Compound Annual Growth Rate | 18.2% |
| Regions Covered | Global |
Premium Insights
- Ongoing Research on Viral Vector-Based Cell and Gene Therapies to Drive Market
- Products Segment in US Accounted for Largest Market Share in 2022
- Products Segment to Witness Highest Growth Rate During Forecast Period
- Pharmaceutical & Biopharmaceutical Companies Segment Accounted for Largest Market Share in 2022
- China to Register Highest CAGR During Forecast Period
Market Dynamics
Drivers
- Rising Prevalence of Genetic Disorders, Cancer, and Infectious Diseases
- Availability of Funding for Development of Gene Therapy
- Effectiveness of Viral Vectors
- Ongoing Research on Viral Vector-Based Gene and Cell Therapies
Restraints
- High Operational Costs Associated with Cell and Gene Therapy Manufacturing
- Short Shelf Life of Viral Vectors
Opportunities
- Smart Capital Deployment and Planning for Scalability
- Leveraging Digital Tools to Facilitate Operational Excellence
Challenges
- Risk of Mutagenesis and Other Unwanted Outcomes
- Individual Optimization and Low Yield
Indicative Pricing Analysis
Value Chain Analysis
- Value Chain Analysis: Manufacturing Phases Add Maximum Value
- Ecosystem Analysis
Technology Analysis
- Examples of Advanced Products/Platforms
Patent Analysis
- Top Patent Owners in Viral Vector and Plasmid DNA Manufacturing Market, January 2014 to January 2023
- Examples of Recent Patent Activity in Viral Vector and Plasmid DNA Manufacturing Market
Trends/Disruptions Impacting Customers' Businesses
- Revenue Shift and New Revenue Pockets for Viral Vector and Plasmid DNA Manufacturers
Regulatory Analysis
Company Profiles
Key Companies
- Lonza Group
- Merck KGaA
- Thermo Fisher Scientific Inc.
- Charles River Laboratories International, Inc.
- Catalent, Inc.
- Wuxi Apptec Co. Ltd.
- Fujifilm Corporation
- Genscript Biotech Corporation
- Takara Bio Inc.
- Oxford Biomedica
- Novartis Ag
- Precision Biosciences
- Bluebird Bio, Inc.
- Sartorius Ag
- Danaher Corporation
- Sirion Biotech
Other Players
- Vgxi, Inc.
- Waisman Biomanufacturing
- Kaneka Eurogentec S.A.
- Plasmidfactory GmbH
- Atum
- Addgene
- Cell and Gene Therapy Catapult
- Batavia Biosciences B.V.
- Altogen Biosystems
For more information about this report visit https://www.researchandmarkets.com/r/pq4k1u
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Attachment
